Current approaches to assess HIV-1 persistence

Current Opinion in HIV and AIDS

Volumn 11, Issue 4, 2016, Pages 424-431

  Banga, Riddhima ^a   Procopio, Francesco A ^a   Perreau, Matthieu ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

integrated HIV DNA; quantitative viral outgrowth assay; tat rev induced limiting dilution analysis

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; INTEGRASE INHIBITOR; VIRUS DNA; ANTIRETROVIRUS AGENT;

ANTIVIRAL THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MOLECULAR EVOLUTION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; VIROGENESIS; VIRUS GENOME; VIRUS REPLICATION; HIV INFECTIONS; PROCEDURES; TRENDS; VIROLOGY; VIRUS LATENCY; VIRUS LOAD;

ANTI-RETROVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HUMANS; VIRAL LOAD; VIRUS LATENCY;

EID: 84964063359     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000282     Document Type: Review

References (63)

1. Palella FJ, Armon C, Buchacz K, et al. Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV Outpatient Study (HOPS). J Antimicrob Chemother 2014; 69:2826-2834.
2. Williams G, Lima V, Gouws E. Modelling the impact of antiretroviral therapy on the epidemic of HIV. Curr HIV Res 2011; 9:367-382.
3. Ruiz L, Martinez-Picado J, Romeu J, et al. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS 2000; 14:397-403.
4. Chun T-W, Nickle DC, Justement JS, et al. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest 2005; 115:3250-3255.
5. Chun T-W, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 1997; 94:13193-13197.
6. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15:893-900.
7. Wong JK, Hezareh M, Günthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278:1291-1295.
8. Heaton R, Clifford D, Franklin D, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy CHARTER Study. Neurology 2010; 75:2087-2096.
9. Muciaccia B, Filippini A, Ziparo E, et al. Testicular germ cells of HIV-seropositive asymptomatic men are infected by the virus. J Reprod Immunol 1998; 41:81-93.
10. Eisele E, Siliciano RF. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 2012; 37:377-388.
11. Van Lint C, Bouchat S, Marcello A. HIV-1 transcription and latency: an update. Retrovirology 2013; 10:1.
12. Deeks SG, Autran B, Berkhout B, et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012; 12:607-614.
13. Pegu A, Asokan M, Wu L, et al. Activation and lysis of human CD4 cells latently infected with HIV-1. Nat Commun 2015; 6:8447.
14. Perreau M, Savoye A-L, De Crignis E, et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med 2013; 210:143-156.
15. Gosselin A, Monteiro P, Chomont N, et al. Peripheral blood CCR4+ CCR6+ and CXCR3+ CCR6+ CD4+ T cells are highly permissive to HIV-1 infection. J Immunol 2010; 184:1604-1616.
16. Yukl SA, Shergill AK, Ho T, et al. The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: implications for viral persistence. J Infect Dis 2013; 208:1212-1220.
17. Buzon MJ, Sun H, Li C, et al. HIV-1 persistence in CD4+T cells with stem celllike properties. Nat Med 2014; 20:139-142
18. Archin N, Liberty A, Kashuba A, et al. Administration of vorinostat disrupts HIV- 1 latency in patients on antiretroviral therapy. Nature 2012; 487:482-485.
19. Rasmussen TA, Tolstrup M, Brinkmann CR, et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 2014; 1:e13-e21.
20. Wei DG, Chiang V, Fyne E, et al. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog 2014; 10:e1004071.
21. Piatak M Jr, Luk K, Williams B, Lifson J, et al. Quantitative competitive polymerase chain reaction for accurate quantitation of HIV DNA and RNA species. Biotechniques 1993; 14:70-81.
22. Ibáñez A, Puig T, Elias J, et al. Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients. AIDS 1999; 13:1045-1049.
23. Butler SL, Hansen MS, Bushman FD. A quantitative assay for HIV DNA integration in vivo. Nat Med 2001; 7:631-634.
24. Strain MC, Lada SM, Luong T, et al. Highly precise measurement of HIV DNA by droplet digital PCR. PLoS One 2013; 8:e55943.
25. Hong F, Aga E, Cillo A, et al. Novel assays tomeasure total cell-associated HIV-1 DNA and RNA. J Clin Microbiol 2016; JCM. 02904-15 [Epub ahead of print]
26. Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003; 9:727-728.
27. Eriksson S, Graf EH, Dahl V, et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog 2013; 9:e1003174.
28. Liszewski MK, Jianqing JY, O'Doherty U. Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR. Methods 2009; 47:254-260.
29. Graf EH, O'Doherty U. Quantitation of integrated proviral DNA in viral reservoirs. Curr Opin HIV AIDS 2013; 8:100-105.
30. Søgaard OS, Graversen ME, Leth S, et al. The depsipeptide romidepsin reverses HIV-1 latency in vivo. PLoS Pathog 2015; 11:e1005142.
31. Sharkey M. Tracking episomal HIV DNA: implications for viral persistence and eradication of HIV. Curr Opin HIV AIDS 2013; 8:93-99.
32. Pace MJ, Graf EH, O'Doherty U. HIV 2-long terminal repeat circular DNA is stable in primary CD4+ T cells. Virology 2013; 441:18-21.
33. Buzó n MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010; 16:460-465.
34. Ho Y-C, Shan L, Hosmane NN, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 2013; 155:540-551.
35. Siliciano JD, Siliciano RF. Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods Mol Biol 2005; 304:3-15.
36. Ylisastigui L, Archin NM, Lehrman G, et al. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 2004; 18:1101-1108.
37. Banga R, Procopio F, Cavassini M, Perreau M. In vitro reactivation of replication competent and infectious HIV-1 by HDAC inhibitors. J Virol 2015; 90:1858-1871
38. Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 2014; 20:425-429.
39. Soriano-Sarabia N, Bateson RE, Dahl NP, et al. Quantitation of replicationcompetent HIV-1 in populations of resting CD4+ T cells. J Virol 2014; 88:14070-14077.
40. Chun T-W, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387:183-188.
41. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512-517.
42. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-1300.
43. Cillo AR, Sobolewski MD, Bosch RJ, et al. Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 2014; 111:7078-7083.
44. Laird GM, Eisele EE, Rabi SA, et al. Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog 2013; 9:e1003398.
45. Laird GM, Bullen CK, Rosenbloom DI, et al. Ex vivo analysis identifies effective HIV-1 latency: reversing drug combinations. J Clin Invest 2015; 125:1901-1912.
46. Howell BJ, Wu G, Swanson M, et al. Developing and applying ultrasensitive P24 protein immunoassay for HIV latency. Abstracts of the Seventh International Workshop on HIV Persistence during Therapy, 8-11 December 2015, Miami, Florida, USA. J Virus Eradication 2015; 1(Suppl 1):5.
47. Pasternak AO, Lukashov VV, Berkhout B. Cell-associated HIV RNA: a dynamic biomarker of viral persistence. Retrovirology 2013; 10:41.
48. Fletcher CV, Staskus K, Wietgrefe SW, et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A 2014; 111:2307-2312.
49. Kieffer TL, Finucane MM, Nettles RE, et al. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis 2004; 189:1452-1465.
50. Dinoso JB, Kim SY, Wiegand AM, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A 2009; 106:9403-9408.
51. Archin NM, Bateson R, Tripathy M, et al. HIV-1 expression within resting CD4 T-cells following multiple doses of vorinostat. J Infect Dis 2014; 210:728-735.
52. Procopio FA, Fromentin R, Kulpa DA, et al. A novel assay to measure the magnitude of the inducible viral reservoir in HIV-infected individuals. EBio- Medicine 2015; 2:872-881
53. Spivak AM, Planelles V. HIV-1 eradication: early trials (and tribulations). Trends Mol Med 2016; 22:10-27.
54. Kearney MF, Spindler J, Shao W, et al. Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy. PLoS Pathog 2014; 10:e1004010.
55. Anderson JA, Archin NM, Ince W, et al. Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4+ T cells. J Virol 2011; 85:5220-5223.
56. Evering TH, Mehandru S, Racz P, et al. Absence of HIV-1 evolution in the gutassociated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. PLoS Pathog 2012; 8:e1002506.
57. Cohn LB, Silva IT, Oliveira TY, et al. HIV-1 integration landscape during latent and active infection. Cell 2015; 160:420-432.
58. Wagner TA, McLaughlin S, Garg K, et al. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 2014; 345:570-573.
59. Lorenzo-Redondo R, Fryer HR, Bedford T, et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature 2016; 530:51-56.
60. Maldarelli F, Wu X, Su L, et al. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 2014; 345:179-183.
61. Palmer S, Wiegand AP, Maldarelli F, et al. New real-time reverse transcriptase- initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003; 41:4531-4536.
62. Douek DC, Brenchley JM, Betts MR, et al. HIV preferentially infects HIVspecific CD4+ T cells. Nature 2002; 417:95-98.
63. O'Doherty U, Swiggard WJ, Jeyakumar D, et al. A sensitive, quantitative assay for human immunodeficiency virus type 1 integration. J Virol 2002; 76:10942-10950.